Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 1.00 |
| ▸ | FPGS | Q05932 | 2/20 | 0.89 |
| ▸ | GART | P22102 | 5/20 | 0.75 |
| ▸ | DHFR | P00374 | 1/20 | 0.67 |
| ▸ | ATIC | P31939 | 3/20 | 0.65 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.63 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofolate SCHEMBL258530 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL30051444 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL1069545 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL9879710 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL8030 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL29435894 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL2691812 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL159231 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL29870853 | 1.00 | SOST (1.00) | SOSTFPGSGARTDHFRATIC | |
| Tetrahydrofolate SCHEMBL10358931 | 0.99 | SOST (0.98) | SOSTFPGSGARTDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622913-B2 | Folate salts for medical use | APROFOL AG (CH) | 2026-05-12 | — | — | US | claimed |
| US-12234237-B2 | Folate salts | APROFOL AG (CH) | 2025-02-25 | — | — | US | claimed |
| WO-2025017570-A1 | SYNERGISTIC BIOACTIVE COMPOSITION FOR MODULATING CHOLINE DEHYDROGENASE (CHD) ACTIVITY | Celagenex Research (India) Pvt. Ltd. (IN) | 2025-01-23 | — | — | WO | claimed |
| CN-116514815-B | Preparation method and application of L-5-methyltetrahydrofolate calcium | 北京斯利安药业有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20230416253-A1 | FOLATE SALTS | APROFOL AG (CH) | 2023-12-28 | — | — | US | claimed |
| US-11787808-B2 | Folate salts | APROFOL AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2023-09-07 | — | — | US | claimed |
| US-11690846-B2 | Folate salts for medical use | APROFOL AG | 2023-07-04 | — | — | US | claimed |
| US-20220403051-A1 | A DOTA binding chimeric antigen receptor for cellular therapy | UNIV PENNSYLVANIA (US) | 2022-12-22 | — | — | US | claimed |
| EP-3099816-B1 | ADMINISTRATION REGIME | ISOFOL MEDICAL AB (SE) | 2022-07-06 | — | — | EP | claimed |
| EP-3958874-A1 | A DOTA-BINDING CHIMERIC ANTIGEN RECEPTOR FOR CELLULAR THERAPY | The Trustees of The University of Pennsylvania (US) | 2022-03-02 | — | — | EP | claimed |
| US-20260144016-A1 | METHOD FOR LEVELING WAFER | OLDOWAN INC (KR) | 2026-05-21 | — | — | US | disclosed |
| US-12622913-B2 | Folate salts for medical use | APROFOL AG (CH) | 2026-05-12 | — | — | US | disclosed |
| WO-2026091465-A1 | TETRAHYDROFOLATE METHYLTRANSFERASE MUTANT, GENE ENCODING SAME AND USE THEREOF | 浙江圣达生物药业股份有限公司 | 2026-05-07 | — | — | WO | disclosed |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | BOBBIE BABY INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-1203090-A4 | A RAPID AND SENSITIVE ASSAY FOR HOMOCYSTEINE | UNIV VIRGINIA COMMONWEALTH (US) | 2004-11-24 | — | — | EP | disclosed |
| EP-1203090-A1 | A RAPID AND SENSITIVE ASSAY FOR HOMOCYSTEINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2000077244-A1 | A RAPID AND SENSITIVE ASSAY FOR HOMOCYSTEINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6046017-A | Rapid and sensitive assay for homocysteine | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0579806-B1 | MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF FOLATE METABOLISM DISORDERS | KRAGLER PETER (DE) | 1999-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690846-B2 | Folate salts for medical use | FOLR2, FOLR1, MTHFD1 | SOST 1617/4885FPGS 9/4885GART 425/4885 |
| US-20220403051-A1 | A DOTA binding chimeric antigen receptor for cellular therapy | CD47, SCTR, CD4 | SOST 2629/4885FPGS 2451/4885GART 3422/4885 |
| US-20260144016-A1 | METHOD FOR LEVELING WAFER | SPIN3, SIK1, SIK3 | SOST 237/4885FPGS 4830/4885GART 4720/4885 |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | FOLR2, FOLR1, MTHFD1 | SOST 1573/4885FPGS 11/4885GART 526/4885 |
| US-12622913-B2 | Folate salts for medical use | FOLR2, FOLR1, MTHFD1 | SOST 2142/4885FPGS 16/4885GART 464/4885 |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | SLC19A1, MTHFD1, MTHFD2 | SOST 1558/4885FPGS 41/4885GART 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.